Hadassah follows US centers in implanting embryonic stem cells into eye to … – Jerusalem Post Israel News
Jerusalem Post Israel News |
Hadassah follows US centers in implanting embryonic stem cells into eye to …
Jerusalem Post Israel News Following several attempts by US researchers, ophthalmologists at The Hadassah University Medical Center in Jerusalem’s Ein Kerem have implanted embryonic stem cells into the eyes of a patient with age-related macular degeneration in the hope of … |
Jerusalem Post Israel News |
Hadassah follows US centers in implanting embryonic stem cells into eye to …
Jerusalem Post Israel News Following several attempts by US researchers, ophthalmologists at The Hadassah University Medical Center in Jerusalem’s Ein Kerem have implanted embryonic stem cells into the eyes of a patient with age-related macular degeneration in the hope of … |
Medical Xpress |
Genes physically held in silencing ‘lock-down’ in embryonic stem cells
Medical Xpress The research, reported online in Nature Genetics, presents how key decision-making genes which specify the embryo’s blueprint for subsequent development are physically clustered in the nucleus of embryonic stem cells and maintained in a silent state. |
|
Asterias’s stem cell therapy shows promise in study
Yahoo News (Reuters) – Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. The company’s shares were up 25 percent at $5.26 in mid-day … |
|
Asterias’s stem cell therapy shows promise in study
Reuters Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. The therapy, AST OPC-1, is the first product derived from human embryos to be … |
Reuters |
Asterias’s stem cell therapy shows promise in study
Reuters Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. The company’s shares were up 25 percent at $5.26 in mid-day trading on heavy … |
|
Successful BNC101 IND Submission Paves Way for Development of Promising Cancer …
PR Newswire (press release) “BNC101 is a new class of anti-cancer agent which targets cancer stem cells. Many current drugs do not specifically target cancer stem cells. We believe that specific drugs, such as BNC101, targeting cancer stem cells will reduce the risk of cancer … |